What is the catalog number for Dapiglutide?

The catalog number for Dapiglutide is HY-P3291.

What sizes are available for Dapiglutide?

Dapiglutide is available in the following size(s): 1 mg, 5 mg, 10 mg.

How many pack sizes does Dapiglutide come in?

Dapiglutide is available in 3 different pack sizes.

Is Dapiglutide in stock?

Dapiglutide is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Dapiglutide?

Dapiglutide is manufactured by QuantiMol.

What is the estimated delivery time for Dapiglutide?

Estimated delivery time for Dapiglutide is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Dapiglutide?

The safety data sheet for Dapiglutide is available here: http://file.medchemexpress.com/batch_PDF/HY-P3291/Dapiglutide-SDS-MedChemExpress.pdf.

Dapiglutide

Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R) /Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects[1][2][3].

Product Specifications

CAS Number

2296814-85-0

Product Name Alternative

ZP7570

UNSPSC

12352209

Target

GCGR

Type

Peptides

Related Pathways

GPCR/G Protein

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/dapiglutide.html

Purity

98.52

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(NC(C)(C)C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H](CO)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H]([C@H](O)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCCNC(CC[C@H](NC(CCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(O)=O)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C)C(N[C@@H](CC3=CNC4=CC=CC=C34)C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC5=CNC=N5)C(N[C@@H](CCCCN)C(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC(O)=O)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC6=CNC=N6)N

Molecular Formula

C192H302N46O57

Molecular Weight

4166.79

References & Citations

[1]Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome. 26 June 2019.|[2]Johannes Reiner, et al. Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel. JPEN J Parenter Enteral Nutr. 2022 Jul;46 (5) :1107-1118.|[3]Copenhagen, et al. Anti-obesity Effect of Dapiglutide Alone and in Combination With the Amylin Analog ZP8396 in DIO Rat. obesity. Spring Vol. 30, (Nov 2022) : 11-12.